Similar articles

• Fixation time does not affect the expression of estrogen receptor.

  Ibarra JA, Rogers LW, Kyshtoobayeva A, Bloom K. Ibarra JA, et al. Am J Clin Pathol. 2010 May;133(5):747-55. doi: 10.1309/AJCPPIUHS4GVAR0I. Am J Clin Pathol. 2010. PMID: 20395521
• Oestrogen receptor beta: how should we measure this?

  Speirs V, Carder PJ, Lansdown MR. Speirs V, et al. Br J Cancer. 2002 Sep 9;87(6):687; author reply 688-9. doi: 10.1038/sj.bjc.6600534. Br J Cancer. 2002. PMID: 12237781 Free PMC article.
• An ER activity profile including ER, PR, Bcl-2 and IGF-IR may have potential as selection criterion for letrozole or tamoxifen treatment of patients with advanced breast cancer.

  Henriksen KL, Rasmussen BB, Lykkesfeldt AE, Møller S, Ejlertsen B, Mouridsen HT. Henriksen KL, et al. Acta Oncol. 2009;48(4):522-31. doi: 10.1080/02841860802676383. Acta Oncol. 2009. PMID: 19173092
• Immunohistochemical markers as predictive tools for breast cancer.

  Walker RA. Walker RA. J Clin Pathol. 2008 Jun;61(6):689-96. doi: 10.1136/jcp.2006.041830. Epub 2007 Nov 23. J Clin Pathol. 2008. PMID: 18037665 Review.
• Oestrogen receptor beta in breast cancer: good, bad or still too early to tell?

  Speirs V. Speirs V. J Pathol. 2002 Jun;197(2):143-7. doi: 10.1002/path.1072. J Pathol. 2002. PMID: 12015736 Review.